Company Profile

Previous Hold Today ACRX ranks #2136 as HOLD CANDIDATE. Next Hold
Today ACRX ranks #2136 as HOLD CANDIDATE.

ACRX stock AcelRx Pharmaceuticals

ACRX stock
AcelRx Pharmaceuticals

AcelRx Pharmaceuticals

351 Galveston Drive

Redwood City, CA 94063

650-216-3500

www.acelrx.com


Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain in the United States. The company’s lead product candidates include ARX-04, a sufentanil sublingual tablet that is in Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings; and Zalviso, a sufentanil sublingual tablet system, which is in Phase III clinical trials for the treatment of moderate-to-severe acute pain in hospitalized adult patients. It is also developing ARX-03, a fixed-dose sufentanil/triazolam sublingual tablet, which has been completed Phase II clinical trial for mild sedation and pain relief during painful procedures. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank